Filtered By:
Source: European Heart Journal
Condition: Peripheral Vascular Disease (PVD)
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
ConclusionCOMPASS-Eligible patients represent a substantial fraction of stable CAD/PAD patients encountered in routine clinical practice in the large international REACH registry suggesting good external applicability. COMPASS-Eligible patients experienced a higher rate of the primary outcome compared with COMPASS participants in the aspirin alone treatment arm.
Source: European Heart Journal - November 23, 2017 Category: Cardiology Source Type: research
